{"id":10577,"date":"2021-03-23T09:00:00","date_gmt":"2021-03-23T08:00:00","guid":{"rendered":"https:\/\/www.emergers.se\/?p=10577"},"modified":"2021-03-23T09:59:33","modified_gmt":"2021-03-23T08:59:33","slug":"lipigon_cv","status":"publish","type":"post","link":"https:\/\/dev.emergers.se\/en\/lipigon_cv\/","title":{"rendered":"Goda utsikter f\u00f6r tidig utlicensiering | Se intervju med vd Stefan K Nilsson"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

Med projekt baserade p\u00e5 h\u00f6gaktuella terapeutiska teknologier som genterapi och RNA-l\u00e4kemedel fokuserar Lipigon<\/span><\/strong>\u00a0p\u00e5 sjukdomar orsakade av st\u00f6rningar i kroppens fettoms\u00e4ttning. Se v\u00e5r intervju med vd Stefan K Nilsson om status p\u00e5 bolagets projekt, m\u00f6jligheterna till tidig utlicensiering och fokus 2021.<\/strong><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n

Johan Widmark | Date:<\/strong> 2021-03-23 <\/span><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
ANALYSKOMMENTAR: Nischindikationer med snabb v\u00e4g till utlicensiering<\/h5>

Lipigon fokuserar p\u00e5 lipidbiologi d\u00e4r man knyter till sig experter inom olika terapeutiska teknologiomr\u00e5den. Lipigons projekt Lipisense (P1), Lipodystrofi (P2) och Dyslipidemi (P3) \u00e4r framf\u00f6rallt inriktade p\u00e5 nischindikationer som kan ge s\u00e4rl\u00e4kemedelsstatus, d\u00e4r P1 och P3 v\u00e4ntas kunna ut\u00f6kas till bredare indikationer med miljardoms\u00e4ttning. F\u00f6r huvudprojektet Lipisense, som utvecklas mot sjukdomarna familj\u00e4r kylomikronemi (FCS) och sv\u00e5r hypertriglyceridemi (SHTG), r\u00e4cker det att p\u00e5visa triglycerids\u00e4nkning och s\u00e4kerhet f\u00f6r f\u00e5 marknadsgodk\u00e4nnande. Bolaget r\u00e4knar med att starta kliniska fas 1-studier under 2022, d\u00e4r effektm\u00e5tt i m\u00e4nniska \u00f6ppnar upp f\u00f6r tidig utlicensiering. Relevanta j\u00e4mf\u00f6relseaff\u00e4rer visar mycket h\u00f6ga belopp (>75 MUSD upfront) \u00e4ven i tidiga faser.<\/p>

Effektdata och m\u00f6jligt licensavtal st\u00f6djer h\u00f6g potential<\/h5>

Sammantaget forts\u00e4tter vi se ett samlat riskjusterat nettonuv\u00e4rde f\u00f6r bolagets projekt p\u00e5 motsvarande 28-35 SEK per aktie p\u00e5 18-24 m\u00e5naders sikt, som inkluderar en riskjusterad f\u00f6rv\u00e4ntan om en utlicensiering av Lipisense. Som med all l\u00e4kemedelsutveckling \u00e4r dock den h\u00f6ga potentialen ocks\u00e5 f\u00f6rknippad med h\u00f6g risk.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\tL\u00c4S ANALYS I PDF H\u00c4R<\/span>\n\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

L\u00e4s v\u00e5r initieringsanalys p\u00e5 Lipigon h\u00e4r\u00a0<\/span><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

Johan Widmark | Tel: 0739196641 | Mail: johan@emergers.se<\/a><\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t

DISCLAIMER<\/strong>
Information som tillhandah\u00e5lls p\u00e5 eller via denna webbplats \u00e4r inte avsedd att vara finansiell r\u00e5dgivning. Emergers mottar ers\u00e4ttning f\u00f6r att skriva om bolaget p\u00e5 den h\u00e4r sidan. Bolaget har givits m\u00f6jlighet att p\u00e5verka faktap\u00e5st\u00e5enden f\u00f6re publicering, men prognoser, slutsatser och v\u00e4rderingsresonemang \u00e4r Emergers egna. F\u00f6r att undvika intressekonflikter har Emergers skribenter inga innehav i de noterade bolag vi skriver om. Analysartiklar skall ej betraktas som en rekommendation eller uppmaning att investera i bolagen som det skrivs om. Emergers kan ej garantera att de slutsatser som presenteras i analysen kommer att uppfyllas. Emergers kan ej h\u00e5llas ansvariga f\u00f6r vare sig direkta eller indirekta skador som orsakats av beslut fattade p\u00e5 grundval av information i denna analys. Investerare uppmanas att komplettera med ytterligare material och information samt konsultera en finansiell r\u00e5dgivare inf\u00f6r alla investeringsbeslut. F\u00f6r fullst\u00e4ndiga villkor se here<\/a>.<\/p>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Med projekt baserade p\u00e5 h\u00f6gaktuella terapeutiska teknologier som genterapi och RNA-l\u00e4kemedel fokuserar Lipigon\u00a0p\u00e5 sjukdomar orsakade av st\u00f6rningar i kroppens fettoms\u00e4ttning. Se v\u00e5r intervju med vd Stefan K Nilsson om status p\u00e5 bolagets projekt, m\u00f6jligheterna till tidig utlicensiering och fokus 2021. Johan Widmark | Datum: 2021-03-23  https:\/\/youtu.be\/9iJWCgGfbY8 ANALYSKOMMENTAR: Nischindikationer med snabb v\u00e4g till utlicensiering Lipigon fokuserar …<\/p>\n<\/div>","protected":false},"author":1,"featured_media":9994,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"spay_email":""},"categories":[54],"tags":[51,43],"jetpack_featured_media_url":"https:\/\/dev.emergers.se\/wp-content\/uploads\/2020\/02\/Lipigon_iStock-1088911666.jpg","_links":{"self":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts\/10577"}],"collection":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/comments?post=10577"}],"version-history":[{"count":19,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts\/10577\/revisions"}],"predecessor-version":[{"id":10608,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/posts\/10577\/revisions\/10608"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/media\/9994"}],"wp:attachment":[{"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/media?parent=10577"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/categories?post=10577"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dev.emergers.se\/en\/wp-json\/wp\/v2\/tags?post=10577"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}